Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sponsor: Celgene Corporation
Listed as NCT02077166, this PHASE1/PHASE2 trial focuses on Refractory Diffuse Large B-Cell Lymphoma and Relapsed Diffuse Large B-Cell Lymphoma and remains completed. Sponsored by Celgene Corporation, it has been updated 20 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
20 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Feb 2021 — Mar 2022 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 15 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2018 — Nov 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Oct 2017 — Mar 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2017 — Oct 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene Corporation
- Janssen Research & Development, LLC
- Pharmacyclics LLC.
For direct contact, visit the study record on ClinicalTrials.gov .